Virpax Pharmaceuticals Inc Aktie News

Virpax Pharmaceuticals (NASDAQ: VRPX ) stock is down on Wednesday as the preclinical-stage pharmaceutical company's lackluster earnings report yesterday continues to weigh on its shares today. Considering the stage of the company's drug development pipeline, its lack of revenue for the quarter makes sense.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Pricing of $2.25M Public Offering.

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 First Quarter Results and Recent Developments.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of MTD Study for Probudur. Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief.

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 Year-End Results.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Preliminary Results of Probudur™ Pilot Study with the U.S. Army Institute of Surgical Research.